The value of the Hb/RDW ratio as a prognostic measure was evaluated in lung cancer, upper tract urothelial carcinoma, esophageal carcinoma, renal cell cancer, bladder cancer, gastric carcinoma, lymphoma, head and neck cancer, breast cancer, and nasopharyngeal cancer. This evidence concerns the gene GSTM1 and breast carcinoma.